Target intelligence / Profile preview

Babesia gibsoni P-type sodium-transporting ATPase 4 (BgATP4) (BgATP4)

Target
BgATP4
Molecular classification
Enzyme, Transporter, P-type ATPase, Sodium-transporting ATPase
01

Overview

Babesia gibsoni P-type sodium-transporting ATPase 4 (BgATP4) is a vital transmembrane enzyme located on the plasma membrane of the protozoan parasite Babesia gibsoni, the causative agent of canine babesiosis (Murata et al., 2018, PMID: 30145158). Its primary biological function is the active extrusion of sodium ions from the parasite's cytoplasm to maintain a low intracellular sodium environment, which is crucial for osmotic balance and nutrient uptake (Spillman et al., 2013, PMID: 23510330). BgATP4 is a validated therapeutic target, as its inhibition by compounds such as spiroindolones (e.g., cipargamin) disrupts sodium homeostasis, leading to rapid influx of water, osmotic swelling, and subsequent lysis of the parasite. Because BgATP4 is structurally distinct from mammalian sodium-potassium ATPases, it offers a high degree of selectivity for antiprotozoal drug development. However, the clinical utility of targeting BgATP4 is challenged by the relative ease with which the parasite can develop resistance through specific point mutations in the ATP4 gene, such as those observed in laboratory-selected resistant strains (Murata et al., 2018, PMID: 30145158).

Other names
BgATP4P-type Na+-ATPaseSodium-extruding ATPaseATPase 4
02

Mechanism of action

Inhibition of the P-type Na+-ATPase leads to an increase in intracellular sodium concentration, resulting in osmotic stress, cellular swelling, and parasite death (Murata et al., 2018, PMID: 30145158).

03

Biological functions

Ion transportSodium homeostasisOsmoregulation
04

Disease associations

Infection
05

Safety considerations

Rapid emergence of resistance through point mutations in the BgATP4 gene (Murata et al., 2018, PMID: 30145158)Potential for cross-resistance among different ATP4 inhibitor classes
06

Interacting drugs

Cipargamin (KAE609)

3 more in the full profile.

07

Biomarkers

BgATP4 gene mutations (e.g., G378V, L382F) (Murata et al., 2018, PMID: 30145158)

Beyond the preview

Go deeper on Babesia gibsoni P-type sodium-transporting ATPase 4 (BgATP4) (BgATP4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Babesia gibsoni P-type sodium-transporting ATPase 4 (BgATP4) (BgATP4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call